Leadership Overview
Regeneron has 5 executives leading key functions including corporate strategy, human resources, regulatory compliance, clinical development, and scientific innovation.
Driven by a commitment to advanced biotechnology, Regeneron delivers life-changing medicines for serious diseases through proprietary science and rigorous research, aiming to transform patient outcomes globally.
Driven by a commitment to advanced biotechnology, Regeneron delivers life-changing medicines for serious diseases through proprietary science and rigorous research, aiming to transform patient outcomes globally.
Leadership Roles at Regeneron
Leonard Schleifer - Co-Chair, President & Chief Executive Officer
Leonard Schleifer, the Co-Chair, President & Chief Executive Officer at Regeneron, directs the overarching corporate strategy and long-term vision for the biotechnology enterprise. Overseeing the discovery and commercialization of innovative medicines, the Chief Executive Officer ensures alignment between scientific research and market needs for serious diseases. This leadership role involves managing complex stakeholder relationships and driving growth across North American and international markets. By prioritizing advanced science, Leonard Schleifer maintains the company's competitive edge in the pharmaceutical sector. Schleifer fosters a culture of innovation that supports the development of treatments for cancer, eye diseases, and inflammatory disorders. Through consistent focus on operational excellence, the Chief Executive Officer secures the financial stability required to sustain high-impact research initiatives. Ultimately, Schleifer guides the organization toward achieving significant breakthroughs in patient care while navigating the evolving regulatory landscape of the global biotechnology industry.

George Yancopoulos - President & Scientific Office Chief & Co-Founder
George Yancopoulos, the President & Scientific Office Chief & Co-Founder at Regeneron, directs the core scientific research and discovery engine that defines the company's biotechnology portfolio. Overseeing the development of proprietary technologies, the Scientific Office Chief ensures that the organization remains at the forefront of innovation for cancer and rare disease treatments. This leadership role involves guiding the research strategy and fostering a culture of scientific excellence that drives the creation of life-changing medicines. By championing advanced research methodologies, George Yancopoulos maintains the company's position as a pioneer in the pharmaceutical industry. Yancopoulos collaborates with internal teams to translate complex biological insights into viable therapeutic candidates. Through the oversight of the scientific pipeline, the President ensures that the company's research efforts align with the most pressing unmet medical needs. Ultimately, Yancopoulos secures the long-term scientific viability and competitive advantage of the entire organization.
Erin Rohr - Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources
Erin Rohr, the Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources at Regeneron, architects the talent acquisition and organizational development frameworks necessary for a high-growth biotechnology firm. Overseeing human capital initiatives, the Vice President ensures that the workforce remains aligned with the company's mission to discover and commercialize life-changing treatments. This leadership role involves designing performance management systems and fostering an inclusive culture that attracts top-tier scientific talent. By optimizing internal processes, Erin Rohr directly impacts the efficiency of cross-functional teams working on rare disease research. Rohr manages the integration of human resources strategies with broader corporate objectives to support global operations. Through the implementation of robust training programs, the Vice President strengthens the internal capabilities required to sustain long-term innovation. Ultimately, Rohr drives the organizational health and employee engagement levels essential for maintaining the company's status as a leader in pharmaceutical manufacturing.
Kim Brenner - Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality
Kim Brenner, the Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality at Regeneron, directs the critical infrastructure governing regulatory compliance and product safety standards. Overseeing the quality assurance frameworks, the Executive VP ensures that all clinical development processes meet rigorous international benchmarks for patient safety. This leadership role involves managing complex interactions with global health authorities to facilitate the approval of innovative medicines. By streamlining operational workflows, Kim Brenner enhances the speed and reliability of the drug development pipeline. Brenner coordinates with scientific teams to maintain the highest standards of integrity across all manufacturing stages. Through the implementation of advanced quality control systems, the Executive VP mitigates risks associated with the commercialization of treatments for inflammatory disorders and rare diseases. Ultimately, Brenner secures the operational foundation necessary for the company to deliver safe, effective therapies to patients worldwide.
Michelle DeSimone - Genetic Medicines Clinical Development Unit Chief of Staff
Michelle DeSimone, the Genetic Medicines Clinical Development Unit Chief of Staff at Regeneron, executes the operational strategy for the clinical advancement of next-generation genetic therapies. Overseeing the coordination between research units and clinical trial sites, the Chief of Staff ensures that development timelines remain on track for complex therapeutic programs. This leadership role involves managing resource allocation and cross-functional communication to accelerate the transition from laboratory discovery to patient-focused clinical trials. By optimizing the execution of clinical protocols, Michelle DeSimone directly supports the company's mission to address serious diseases through advanced science. DeSimone facilitates the alignment of clinical objectives with broader corporate goals, ensuring that genetic medicine initiatives receive the necessary support for success. Through the management of internal project workflows, the Chief of Staff enhances the efficiency of the development pipeline. Ultimately, DeSimone drives the operational progress required to bring life-changing genetic treatments to market.
Explore Leadership Teams in Manufacturing
Alkem is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company was established in 1973 and is headquartered in Mumbai, India.
Company Leadership SA
YH
AS
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Company Leadership
RI
NB
CS
Humanetics Corporation is a clinical-stage pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs with a focus on medical countermeasures, radiation modulators for oncology and inflammatory lung diseases.
Company Leadership CO
BL
BL
ZW
Founded in 2001 and headquartered in Moscow, Russia, R-Pharm is a pharmaceutical company. The company is involved in R&D, manufacturing (finished dosage forms, biotech and chemical APIs), marketing, sales and distribution of innovative pharmaceutical products in hospital/specialty care therapeutic areas.
Company Leadership OB
AS
BO